论文部分内容阅读
目的探讨重组人血小板生成素联合地塞米松治疗原发免疫性血小板减少症的临床疗效。方法 64例原发免疫性血小板减少症患者,将其随机分成对照组和观察组,每组32例。对照组患者使用地塞米松治疗,观察组患者使用重组人血小板生成素联合地塞米松治疗。比较两组治疗效果。结果治疗后,观察组血小板计数为(132.8±65.6)×10~9/L,高于对照组的(76.8±68.5)×10~9/L,差异有统计学意义(P<0.05);观察组治疗总有效率为84.4%,高于对照组的62.5%,差异具有统计学意义(P<0.05)。观察组不良反应发生率为21.9%,对照组为15.6%,比较差异无统计学意义(P>0.05)。结论重组人血小板生成素联合地塞米松治疗原发免疫性血小板减少症疗效显著,无明显副作用,可在临床推广用。
Objective To investigate the clinical efficacy of recombinant human thrombopoietin combined with dexamethasone in the treatment of primary immune thrombocytopenia. Methods 64 patients with primary immune thrombocytopenia were randomly divided into control group and observation group, 32 cases in each group. Control group patients treated with dexamethasone, observation group patients treated with recombinant human thrombopoietin combined with dexamethasone. Compare the treatment effect of two groups. Results After treatment, the platelet count in observation group was (132.8 ± 65.6) × 10 ~ 9 / L, which was significantly higher than that in control group (76.8 ± 68.5) × 10 ~ 9 / L The total effective rate of the treatment group was 84.4%, higher than that of the control group (62.5%), the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 21.9% and in the control group was 15.6%, with no significant difference (P> 0.05). Conclusion Recombinant human thrombopoietin combined with dexamethasone treatment of primary immune thrombocytopenia significant effect, no significant side effects, can be used in clinical promotion.